Powerwand™ Midline Catheters

Not All Catheters Are Created Equal

Offering intuitive and easy insertion methods, Powerwand midline catheters are designed to reduce the number of steps needed to insert the catheter compared to a standard modified Seldinger technique.

Once in place, Powerwand midline catheters are designed to last up to 29 days and provide full completion of IV therapy. Multiple independent studies demonstrated that use of Powerwand catheters, coupled with additional clinical measures, showed a reduction in occurrence of bloodstream infections.^{2, 3, 4, 5}

The Powerwand

Shown to inhibit bacterial attachment (in vitro)2
Shown to reduce thrombus formation (in vivo)1
Multiple independent studies demonstrated that use of Powerwand catheters, coupled with additional clinical measures, showed a reduction in occurrence of bloodstream infections.2-5
High power injection rating: 8 mL/sec, 325 psi
High flow rates: 75-185 mL/min

Echogenic properties of the Powerwand catheter allow for ultrasound visualization once in the vein.

Thermoformed Tip

The Powerwand catheter tip is thermoformed to avoid jagged edges.

Thromboresistant

The Powerwand catheter is shown in vivo to resist thrombus formation with respect to thrombus on the surface of the catheter and thrombus on the wall of the vein, as compared with a commonly used control device.²

Kink Resistance

The unique material, CHRONOFLEX C^®, of the Powerwand^™ catheter is designed to be kink resistant to provide reliability during both insertion and dwell times

Powerwand Kits and Accessories

Product Information

Literature

Supporting Evidence

CHRONOFLEX C is a trademark of Advansource Biomaterials Corporation

Product inquiry

Please enter your details into the following form.

1
2

Comments *

First name *

Last name *

Email address *

References

FDA-cleared 510(k) Powerwand has shown in vivo to be thromboresistant with respect to both thrombus on the surface of the catheter and thrombus on the wall of the vein, based upon 72-hour canine jugular vein thromboresistance studies. This per clinical in vivo evaluation does not necessarily predict clinical performance with respect to thrombus formation.
Pathak R, Bierman SF, d’Arnaud P. Inhibition of bacterial attachment and biofilm formation by a novel intravenous catheter material using an in vitro percutaneous catheter insertion model. Med Devices (Auckl). 2018 Dec 19;11:427-432. doi: 10.2147/MDER.S183409. PMID: 30588133; PMCID: PMC6305250
DeVries M, Lee J, Hoffman L. Infection free midline catheter implementation at a community hospital (2 years). Am J Infect Control. 2019;47(9):1118-1121.
Caparas JV, Hung HS. Vancomycin administration through a novel midline catheter: summary of a 5-year, 1086-patient experience in an urban community hospital. J Vasc Access. J Vasc Access 2017;22(1):38-41.
Pathak R, Patel A, Enuh H, et al. The incidence of central line-associated bacteremia after the introduction of midline catheters in a ventilator unit population. Infect Dis Clin Pract (Baltim Md). 2015;23(3):131-134.

Powerwand^™ Midline Catheters